血管紧张素转换酶2在新型冠状病毒感染及治疗中的作用概述  

Role of Angiotensin Converting Enzyme 2 in Infection and Treatment of SARS-CoV-2

作　　者：颜辉 徐璐扬 邱晓燕 Yan Hui;Xu Luyang;Qiu Xiaoyan(Department of Pharmacy,Huashan Hospital Affiliated to Fudan University,Shanghai 200040,China;Department of Pharmacy,the First Affiliated Hospital of USTC Division of Life Sciences and Medicine,University of Science and Technology of China)

机构地区：[1]复旦大学附属华山医院药剂科,上海200040 [2]中国科学技术大学附属第一医院/安徽省立医院药剂科

出　　处：《药物流行病学杂志》2020年第5期342-346,共5页Chinese Journal of Pharmacoepidemiology

基　　金：上海市“医苑新星”青年医学人才培养资助计划-临床药师项目(编号:沪卫计药政[2018]1号);上海市2019年度“科技创新行动计划”软科学研究领域重点项目(编号:19692107000);2019年上海市临床重点专科项目-临床药学专业(编号:shslczdzk06502)。

摘　　要：血管紧张素转换酶2(ACE2)是肾素-血管紧张素系统(RAS)重要的组成部分,能够下调RAS,具有抗炎、抗纤维化等作用。同时ACE2还是新型冠状病毒(SARS-CoV-2)的受体,与SARS-CoV-2感染及感染后的临床表现密切相关。血管紧张素转化酶抑制药/血管紧张素Ⅱ受体阻断药(ACEI/ARB)在SARS-CoV-2感染中的作用,目前研究尚有争议。本文对ACE2及ACEI/ARB类药物在SARS-CoV-2感染中的作用作一综述。基于目前的研究证据,建议感染前已使用ACEI/ARB类药物的新型冠状病毒肺炎(COVID-19)患者继续用药,但目前尚不建议将ACEI/ARB类药物用于COVID-19患者的治疗。Angiotensin converting enzyme 2(ACE2),a homologue of ACE,is an important component of the renin-angiotensin system(RAS),which can down-regulate RAS with anti-inflammatory and anti-fibrotic effects.And ACE2 is also a receptor for SARS-CoV-2,and is closely related to SARS-CoV-2 infection and subsequent clinical manifestations.The role of drugs such as angiotensin converting enzyme inhibitor/angiotensinⅡreceptor blocker(ACEI/ARB)in SARS-CoV-2 infection is currently controversial.This paper reviewed the role of ACE2 and ACEI/ARB in SARS-CoV-2 infection.Based on the current research evidence,it is recommended that patients with Corona Virus Disease 2019(COVID-19)who have already taken ACEI/ARB before infection continue to take the drugs,but ACEI/ARB are not recommended for the treatment of COVID-19 patients.

关 键 词：新型冠状病毒 新型冠状病毒肺炎 血管紧张素转换酶2 血管紧张素转化酶抑制药/血管紧张素Ⅱ受体阻断药 

分 类 号：R373.1[医药卫生—病原生物学]